Analyst firms · Morgan Stanley · DXCM
Morgan Stanley DXCM price target and rating history
DexCom Inc. (DXCM) · Health Care
Morgan Stanley rates DexCom Inc. (DXCM) Overweight with a $75 price target, as of its latest action on Dec 2, 2025. It has published 5 rating actions on DXCM since October 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a DXCM price target in the last 12 months, the median target is $86. Morgan Stanley's $75 is 13% below that.
- Current rating
- Overweight
- Price target
- $75
- Median target, all firms
- $86
- Actions on DXCM
- 5
Morgan Stanley price target on DXCM
Every Morgan Stanley rating on DXCM
- Dec 2, 2025
- May 30, 2023
- Feb 11, 2022
- Jan 7, 2022
- Oct 29, 2021
How other firms rate DXCM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $115 | Oct 7, 2026 |
| Deutsche Bank | Buy | $86 | Jun 23, 2026 |
| The Benchmark Company | Buy | $77 | May 12, 2026 |
| Evercore ISI | Outperform | $90 | Mar 24, 2026 |
| Morgan Stanley | Overweight | $75 | Dec 2, 2025 |
Questions about Morgan Stanley and DXCM
- What is Morgan Stanley's price target for DXCM?
- Morgan Stanley's latest stated price target for DexCom Inc. (DXCM) is $75, from its action on Dec 2, 2025.
- What is Morgan Stanley's rating on DXCM?
- Morgan Stanley rates DXCM Overweight, a bullish rating, as of Dec 2, 2025.
- When did Morgan Stanley last change its view on DXCM?
- On Dec 2, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $75.
- How does Morgan Stanley's DXCM target compare with other analysts?
- Across 5 firms with a DXCM price target in the last 12 months, the median target is $86. Morgan Stanley's $75 is 13% below that.
More DXCM rating histories
All Morgan Stanley ratingsDXCM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.